Three Reasons Growth in the Mammography Systems Market is Set to Slow

With over 250 unique vendors operating in the market to date and new funding announcements seemingly published every week, investors are clearly confident in the future of AI technology for drug development and clinical trials. This was exemplified with Exscientia’s massive Series D funding round in later April 2021.

Whilst growth in the overall digital pathology AI market is set to scale quickly, cannibalisation and consolidation are expected to create headwinds for individual AI vendors. How do investors know where their money is safest?

The launch of NVIDIA's Cambridge-1 Supercomputer signals a bullish outlook from the firm for the future development of the AI in healthcare market. Cambridge-1's list of potential applications ranges across healthcare domains, with partnerships geared towards medical imaging, genomics and drug development.